How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? - PubMed (original) (raw)
. 2010 Dec 14;411(23-24):1906-14.
doi: 10.1016/j.cca.2010.07.038. Epub 2010 Aug 14.
Aimé Ntwari, Joe T R Clarke, David G Warnock, João Paulo Oliveira, Sarah P Young, David S Millington, Daniel G Bichet, Sandra Sirrs, Michael L West, Robin Casey, Wuh-Liang Hwu, Joan M Keutzer, X Kate Zhang, René Gagnon
Affiliations
- PMID: 20716442
- DOI: 10.1016/j.cca.2010.07.038
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
Christiane Auray-Blais et al. Clin Chim Acta. 2010.
Abstract
Background: Fabry disease is characterized by accumulation of glycosphingolipids, such as globotriaosylceramide (Gb(3)), in many tissues and body fluids. A novel plasma biomarker, globotriaosylsphingosine (lyso-Gb(3)), is increased in patients with the disease. Until now, lyso-Gb(3) was not detectable in urine, possibly because of the presence of interfering compounds.
Methods: We undertook to: 1) characterize lyso-Gb(3) in urine; 2) develop a method to quantitate urinary lyso-Gb(3) by mass spectrometry; 3) evaluate urinary lyso-Gb(3) as a potential biomarker for Fabry disease; and 4) determine whether lyso-Gb(3) is an inhibitor of α-galactosidase A activity. We analyzed urinary lyso-Gb(3) from 83 Fabry patients and 77 healthy age-matched controls.
Results: The intraday and interday bias and precision of the method were <15%. Increases in lyso-Gb(3)/creatinine correlated with the concentrations of Gb(3) (r(2)=0.43), type of mutations (p=0.0006), gender (p<0.0001) and enzyme replacement therapy status (p=0.0012). Urine from healthy controls contained no detectable lyso-Gb(3). Lyso-Gb(3) did not inhibit GLA activity in dried blood spots. Increased urinary excretion of lyso-Gb(3) of Fabry patients correlated well with a number of indicators of disease severity.
Conclusion: Lyso-Gb(3) is a reliable independent biomarker for clinically important characteristics of Fabry disease.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
- Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P, Boutin M, Auray-Blais C. Lavoie P, et al. Anal Chem. 2013 Feb 5;85(3):1743-52. doi: 10.1021/ac303033v. Epub 2013 Jan 7. Anal Chem. 2013. PMID: 23248976 Clinical Trial. - Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.
Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JT. Auray-Blais C, et al. Anal Chem. 2012 Mar 20;84(6):2745-53. doi: 10.1021/ac203433e. Epub 2012 Feb 28. Anal Chem. 2012. PMID: 22309310 - Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, Kanekura T, Sakuraba H. Togawa T, et al. Biochem Biophys Res Commun. 2010 Sep 3;399(4):716-20. doi: 10.1016/j.bbrc.2010.08.006. Epub 2010 Aug 6. Biochem Biophys Res Commun. 2010. PMID: 20692233 - Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J, Weidemann F. Kramer J, et al. Curr Med Chem. 2018;25(13):1530-1537. doi: 10.2174/0929867324666170616102112. Curr Med Chem. 2018. PMID: 28618999 Review. - Lipiduria--with special relevance to Fabry disease.
Becker GJ, Nicholls K. Becker GJ, et al. Clin Chem Lab Med. 2015 Nov;53 Suppl 2:s1465-70. doi: 10.1515/cclm-2015-0499. Clin Chem Lab Med. 2015. PMID: 26124059 Review.
Cited by
- Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects.
Rocchetti MT, Spadaccino F, Catalano V, Zaza G, Stallone G, Fiocco D, Netti GS, Ranieri E. Rocchetti MT, et al. Metabolites. 2022 Jul 28;12(8):703. doi: 10.3390/metabo12080703. Metabolites. 2022. PMID: 36005574 Free PMC article. Review. - Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.
Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, Kramer G, Poorthuis BJ, Groener JE, Cox-Brinkman J, Rombach SM, Hollak CE, Linthorst GE, Witte MD, Gold H, van der Marel GA, Overkleeft HS, Boot RG. Aerts JM, et al. J Inherit Metab Dis. 2011 Jun;34(3):605-19. doi: 10.1007/s10545-011-9308-6. Epub 2011 Mar 29. J Inherit Metab Dis. 2011. PMID: 21445610 Free PMC article. Review. - Lipidomics of glycosphingolipids.
Farwanah H, Kolter T. Farwanah H, et al. Metabolites. 2012 Feb 2;2(1):134-64. doi: 10.3390/metabo2010134. Metabolites. 2012. PMID: 24957371 Free PMC article. - Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
Gaggl M, Lajic N, Heinze G, Voigtländer T, Sunder-Plassmann R, Paschke E, Fauler G, Sunder-Plassmann G, Mundigler G. Gaggl M, et al. Int J Med Sci. 2016 Apr 26;13(5):340-6. doi: 10.7150/ijms.14997. eCollection 2016. Int J Med Sci. 2016. PMID: 27226774 Free PMC article. - Broad spectrum of Fabry disease manifestation in an extended Spanish family with a new deletion in the GLA gene.
Lukas J, Torras J, Navarro I, Giese AK, Böttcher T, Mascher H, Lackner KJ, Fauler G, Paschke E, Cruzado JM, Dudesek A, Wittstock M, Meyer W, Rolfs A. Lukas J, et al. Clin Kidney J. 2012 Oct;5(5):395-400. doi: 10.1093/ckj/sfs115. Clin Kidney J. 2012. PMID: 26019814 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical